On March 3, 2021, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Furmonertinib Mesylate Tablets (trade name: Alflutinib), a Class 1 innovative drug filed by Shanghai Elpiscience Pharmaceutical Technology Co., Ltd., through the priority review and approval procedure.
As an innovative drug independently developed in China with
independent intellectual property rights, this medicine is indicated for the
treatment of adult patients with locally advanced or metastatic non-small cell
lung cancer (NSCLC) who have experienced disease progression during or after
prior treatment with epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) and are confirmed by testing to be EGFR T790M
mutation-positive.
This drug is a third-generation epidermal growth factor receptor (EGFR) kinase inhibitor. Its marketing has provided a new treatment option for adult patients with non-small cell lung cancer (NSCLC).
